Li, Ruitong
Klingbeil, Olaf
Monducci, Davide http://orcid.org/0000-0002-6761-1207
Young, Michael J. http://orcid.org/0000-0002-9167-2413
Rodriguez, Diego J. http://orcid.org/0000-0002-0053-8674
Bayyat, Zaid http://orcid.org/0000-0001-5080-9607
Dempster, Joshua M. http://orcid.org/0000-0002-3634-9576
Kesar, Devishi
Yang, Xiaoping http://orcid.org/0000-0002-6811-4915
Zamanighomi, Mahdi
Vakoc, Christopher R.
Ito, Takahiro http://orcid.org/0000-0002-7933-5393
Sellers, William R. http://orcid.org/0000-0002-3539-9803
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-19-1-0271)
Ludwig Institute for Cancer Research (500506)
Article History
Received: 5 October 2021
Accepted: 21 April 2022
First Online: 5 May 2022
Competing interests
: W.R.S. during the conduct of this research was or is a Board or SAB member and equity holder in Peloton Therapeutics, Ideaya Biosciences, Civetta Therapeutics, Scorpion Therapeutics, and Bluebird and has consulted for Array, Astex, Dynamo Therapeutics, Ipsen, PearlRiver Bio, Sanofi, and Servier; and receives research funding from Pfizer Pharmaceuticals, Merck, Ideaya Biosciences, Boehringer-Ingelheim, and Deerfield Management. T.I. is an equity holder of Scorpion Therapeutics and Odyssey Therapeutics. C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences, and C4 Therapeutics, has served on the scientific advisory board of KSQ Therapeutics, Syros Pharmaceuticals, and Treeline Biosciences, has received research funding from Boehringer-Ingelheim and Treeline Biosciences and owns a stock option from Treeline Biosciences. The remaining authors declare no competing interests.